Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[123I]NAV5001 for Diagnosis of Parkinsonian Syndromes
NCT01950455Phase 3Terminated
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Nov 2013
- Primary completion
- Jan 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of altropane in parkinsonian syndromes, sponsored by Navidea Biopharmaceuticals, Inc.. Started Nov 2013; status: terminated.
02
Drugs
altropane
03
Conditions
parkinsonian syndromes
Beyond the preview
Go deeper on NCT01950455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01950455.